- Home
- ACLX vs HAE Comparison
ACLX vs HAE Comparison
Compare ACLX & HAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACLX
- HAE
- Stock Information
- Founded
- ACLX 2015
- HAE 1971
- Country
- ACLX United States
- HAE United States
- Employees
- ACLX N/A
- HAE N/A
- Industry
- ACLX Biotechnology: Pharmaceutical Preparations
- HAE Medical/Dental Instruments
- Sector
- ACLX Health Care
- HAE Health Care
- Exchange
- ACLX Nasdaq
- HAE Nasdaq
- Market Cap
- ACLX 3.6B
- HAE 3.6B
- IPO Year
- ACLX 2022
- HAE 1991
- Fundamental
- Price
- ACLX $63.75
- HAE $62.98
- Analyst Decision
- ACLX Strong Buy
- HAE Strong Buy
- Analyst Count
- ACLX 14
- HAE 9
- Target Price
- ACLX $107.67
- HAE $103.56
- AVG Volume (30 Days)
- ACLX 532.8K
- HAE 1.4M
- Earning Date
- ACLX 02-26-2025
- HAE 02-06-2025
- Dividend Yield
- ACLX N/A
- HAE N/A
- EPS Growth
- ACLX N/A
- HAE 3.20
- EPS
- ACLX N/A
- HAE 2.54
- Revenue
- ACLX $155,818,000.00
- HAE $1,373,515,000.00
- Revenue This Year
- ACLX $12.58
- HAE $7.56
- Revenue Next Year
- ACLX N/A
- HAE $3.13
- P/E Ratio
- ACLX N/A
- HAE $24.76
- Revenue Growth
- ACLX 230.33
- HAE 8.14
- 52 Week Low
- ACLX $47.88
- HAE $58.80
- 52 Week High
- ACLX $107.37
- HAE $97.97
- Technical
- Relative Strength Index (RSI)
- ACLX 41.49
- HAE 38.28
- Support Level
- ACLX $62.38
- HAE $58.80
- Resistance Level
- ACLX $67.00
- HAE $65.15
- Average True Range (ATR)
- ACLX 2.82
- HAE 2.76
- MACD
- ACLX 0.32
- HAE 0.34
- Stochastic Oscillator
- ACLX 28.44
- HAE 32.85
About ACLX Arcellx Inc.
Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases.
About HAE Haemonetics Corporation
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company places primary emphasis on its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.